+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Europe Narcolepsy Market to 2027 - Regional Analysis and Forecasts By Type; Distribution Channel and Country

  • ID: 4987828
  • Report
  • January 2020
  • Region: Europe
  • 123 Pages
  • The Insight Partners
UP TO OFF
until Jan 31st 2021

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • BIOPROJET
  • Graymark Healthcare, Inc.
  • Jazz Pharmaceuticals plc
  • Mylan N.V.
  • Novartis AG
  • Shionogi & Co., Ltd.

Europe, the narcolepsy market, is anticipated to reach US$ 1,532.5 Mn in 2027 from US$ 671.1 Mn in 2018. The market is projected to grow with a CAGR of 9.7% from 2019-2027.

The European narcolepsy market is expected to grow due to key driving factors such as growing research and developments and increasing awareness across the region. The market is divided into countries such as Germany, UK, France, Italy, and Spain. In Europe, narcolepsy with cataplexy is a rare disease with an estimated prevalence of 0.02% in European populations. Narcolepsy shares many features of rare disorders, in particular the lack of awareness of the disease with serious consequences for healthcare supply. Similar to other rare diseases, only a few European countries have registered narcolepsy cases in databases of the International Classification of Diseases or in registries of the European health authorities.

Narcolepsy is a rare disease that shows different symptoms in children and adults. The symptoms shown by children are not noticed that much until they reach adulthood. However, the incidences of narcolepsy in children are less and are not estimated due to the undiagnosed of the conditions. According to a study ‘Clinical Characteristics and Burden of Illness in Pediatric Patients with Narcolepsy’ published in 2018 stated that the prevalence of narcolepsy among children between the age of 5 years and below is 13 per 100,000. Whereas, it 83 for every 100,000 children between the age group of 5 years and 19 years. Therefore, it is necessary to raise awareness among the people so as to reduce the symptoms of narcolepsy.

Across, Europe the awareness is increasing significantly, For instance, in Ireland, 22nd September is celebrated as narcolepsy day. Across Ireland, a kite-flying event was conducted. The event was successfully held and the aim to spread awareness of narcolepsy was fulfilled. Similarly in Italy in September 2016, the University of Bologna in collaboration with the Italian Narcolepsy Community conducted a narcolepsy awareness program that involved speakers from Italy, France, and the US to talk about the novel findings and propagate general information to the populace regarding narcolepsy and other sleep-related neurological disorders. Thus, it is estimated that the rising awareness program is likely to influence the growth of the market during the forecast period.

The European narcolepsy market is segmented as type, product and distribution channels. Based on type the market is segmented as narcolepsy with cataplexy, narcolepsy without cataplexy, and secondary narcolepsy. Based on the product the market is categorized as central nervous system (CNS) stimulants, sodium oxybate, and antidepressants. And based on the distribution channel the market is classified as hospital pharmacies and retail pharmacies.

In 2018, the narcolepsy with cataplexy segment held the largest market share of the narcolepsy market, by type. This segment is expected to dominate the market in 2027 owing to the rising episodes of cataplexy that are expected to be encountered among 55-60% of patients suffering from narcolepsy. The segment is also anticipated to witness the fastest growth rate during the forecast period, 2019 to 2027.

Some of the significant primary and secondary sources for narcolepsy included in the report are the European Commission, European Medicines Agency, European Union, Associazione Italiana di Medicina del Sonno and others.

Reasons to Buy

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the European narcolepsy market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the European narcolepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • BIOPROJET
  • Graymark Healthcare, Inc.
  • Jazz Pharmaceuticals plc
  • Mylan N.V.
  • Novartis AG
  • Shionogi & Co., Ltd.

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance

2. Europe Narcolepsy Market - Key Takeaways

3. Europe Narcolepsy Market - Market Landscape
3.1 Overview
3.2 Market Segmentation
3.2.1 Europe Narcolepsy Market - By Type
3.2.2 Europe Narcolepsy Market - By Product
3.2.3 Europe Narcolepsy Market - By Distribution Channel
3.2.4 Europe Narcolepsy Market - By Country
3.3 PEST Analysis

4. Europe Narcolepsy Market-Key Dynamics
4.1 Key Market Drivers
4.1.1 Growing Research and Developments
4.1.2 Increasing Awareness Across the Region
4.2 Key Market Restraints
4.2.1 Challenge Related to Narcolepsy
4.3 Key Market Opportunity
4.3.1 Reimbursement For Drugs
4.4 Future Trend
4.4.1 Developments in Pharmaceutical Sector to Treat Narcolepsy
4.5 Impact Analysis Of Drivers and Restraints

5. Narcolepsy Market - Regional Analysis
5.1 Europe Narcolepsy Market Revenue Forecasts and Analysis
5.2 Performance Of Key Players
5.2.1 Jazz Pharmaceuticals plc
5.2.2 Teva Pharmaceutical Industries Ltd.

6. Narcolepsy Market Analysis and Forecasts to 2027 - Type
6.1 Overview
6.2 Type Market Revenue and Forecasts Analysis (US$ Mn)
6.3 Europe Narcolepsy With Cataplexy Market Revenue and Forecasts To 2027, By Type (Us$ Mn)
6.4 Narcolepsy With Cataplexy Market
6.4.1 Overview
6.4.2 Narcolepsy With Cataplexy Market Revenue and Forecast to 2027 (US$ Mn)
6.5 Narcolepsy Without Cataplexy Market
6.5.1 Overview
6.5.2 Narcolepsy Without Cataplexy Market Revenue and Forecast to 2027 (US$ Mn)
6.6 Secondary Narcolepsy Market
6.6.1 Overview
6.6.2 Secondary Narcolepsy Market Revenue and Forecast to 2027 (US$ Mn)

7. Narcolepsy Market Analysis and Forecasts to 2027 - Product
7.1 Overview
7.2 Product Market Revenue and Forecasts Analysis (US$ Mn)
7.3 Europe Narcolespy Market Revenue and Forecasts To 2027, By Product (US$ Mn)
7.4 Central Nervous System Stimulants Market
7.4.1 Overview
7.4.2 Central Nervous System Stimulants Market Revenue and Forecast to 2027 (US$ Mn)
7.5 Sodium Oxybate Market
7.5.1 Overview
7.5.2 Sodium Oxybate Market Revenue and Forecast to 2027 (US$ Mn)
7.6 Antidepressants Market
7.6.1 Overview
7.6.2 Antidepressants Market Revenue and Forecast to 2027 (US$ Mn)

8. Narcolepsy Market Analysis and Forecasts to 2027 - Distribution Channel
8.1 Overview
8.2 Distribution Channel Market Revenue and Forecasts Analysis (US$ Mn)
8.3 Europe Narcolespy Market Revenue and Forecasts To 2027, By End User (US$ Mn)
8.4 Hospital Pharmacies Market
8.4.1 Overview
8.4.2 Hospital Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)
8.5 Retail Pharmacies Market
8.5.1 Overview
8.5.2 Retail Pharmacies Market Revenue and Forecast to 2027 (US$ Mn)

9. Narcolepsy Market Revenue And Forecasts To 2027 - Geographical Analysis
9.1 Europe Narcolepsy Market
9.1.1 Overview
9.1.2 Europe Narcolepsy Market Revenue Overview, by Country (2017) (US$ Mn)
9.1.3 Europe Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.4 Europe Narcolepsy Market Revenue And Forecasts to 2027, By Type (US$ Mn)
9.1.5 Europe Narcolepsy Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.6 Europe Narcolepsy Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
9.1.7 Europe Narcolepsy Market Revenue and Forecasts to 2027, By Country (%)
9.1.8 Germany Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.9.1 Germany Narcolepsy Market Revenue And Forecasts to 2027, By Type (US$ Mn)
9.1.9.2 Germany Narcolepsy Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.9.3 Germany Narcolepsy Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
9.1.10 UK Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.11.1 UK Narcolepsy Market Revenue And Forecasts to 2027, By Type (US$ Mn)
9.1.11.2 UK Narcolepsy Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.11.3 UK Narcolepsy Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
9.1.12 France Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.13.1 France Narcolepsy Market Revenue And Forecasts to 2027, By Type (US$ Mn)
9.1.13.2 France Narcolepsy Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.13.3 France Narcolepsy Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
9.1.14 Italy Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.15.1 Italy Narcolepsy Market Revenue And Forecasts to 2027, By Type (US$ Mn)
9.1.15.2 Italy Narcolepsy Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.15.3 Italy Narcolepsy Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)
9.1.16 Spain Narcolepsy Market Revenue and Forecasts to 2027 (US$ Mn)
9.1.17.1 Spain Narcolepsy Market Revenue And Forecasts to 2027, By Type (US$ Mn)
9.1.17.2 Spain Narcolepsy Market Revenue And Forecasts to 2027, By Product (US$ Mn)
9.1.17.3 Spain Narcolepsy Market Revenue And Forecasts to 2027, By Distribution Channel (US$ Mn)

10. Narcolepsy Market - Industry Landscape
10.1 Overview
10.2 Comparative Company Analysis
10.3 Growth Strategies Done By The Companies In The Market, (%)
10.4 Organic Developments
10.4.1 Overview
10.5 Inorganic Developments
10.5.1 Overview

11. Narcolepsy Market -Key Company Profiles
11.1 Teva Pharmaceutical Industries Ltd.
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Financial Overview
11.1.4 Product Portfolio
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Jazz Pharmaceuticals Plc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Financial Overview
11.2.4 Product Portfolio
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Arena Pharmaceuticals, Inc.
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Financial Overview
11.3.4 Product Portfolio
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Graymark Healthcare, Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Financial Information
11.4.4 Product Portfolio
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Novartis AG
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Financial Information
11.5.4 Product Portfolio
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Takeda Pharmaceutical Company Limited
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Financial Information
11.6.4 Product Pipeline
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Mylan N.V.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Financial Overview
11.7.4 Product Portfolio
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Bioprojet
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Financial Overview
11.8.4 Product Portfolio
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Shionogi & Co., Ltd.
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Financial Overview
11.9.4 Product Portfolio
11.9.5 Product Pipeline
11.9.6 SWOT Analysis
11.9.7 Key Developments
11.10 Ligand Pharmaceuticals, Inc.
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Financial Overview
11.10.4 Product Portfolio
11.10.5 Product Pipeline
11.10.6 SWOT Analysis
11.10.7 Key Developments

12. Appendix
12.1 About the Publisher
12.2 Glossary Of Terms
12.3 Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Primary Research

Note: Product cover images may vary from those shown
  • Teva Pharmaceutical Industries Ltd.
  • Jazz Pharmaceuticals plc
  • Arena Pharmaceuticals, Inc.
  • Graymark Healthcare, Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Mylan N.V.
  • BIOPROJET
  • Shionogi & Co., Ltd.
  • Ligand Pharmaceuticals, Inc
Note: Product cover images may vary from those shown
Adroll
adroll